Shruti Chandra

1 month ago | erc.bioscientifica.com | Shruti Chandra |Thorvardur Halfdanarson |Erin Carlson |Kari G. Rabe

Keywords: pancreatic neuroendocrine neoplasms; neuroendocrine cancer; risk factors; panNEN; panNET; nets; NECIntroductionPancreatic neuroendocrine neoplasms (panNENs) are the second most common type of pancreatic cancer, comprising about 2% of cases, with pancreatic ductal adenocarcinoma (PDAC) being the most common type and constitutes roughly 95% of cases (Batcher et al. 2011, Halfdanarson et al. 2014, Antwi et al. 2017).

Nov 22, 2024 | nature.com | Amitha Domalpally |Shruti Chandra

AbstractClinical trials investigating drugs for various stages of age-related macular degeneration (AMD) are actively underway and there is a strong interest in outcomes that demonstrate a structure-function-correlation. The ellipsoid zone (EZ), a crucial anatomical feature affected in this disease, has emerged as a strong contender.

Jul 6, 2024 | nature.com | Shruti Chandra

AbstractTo evaluate the effect of four versus three loading aflibercept injections on macular fluid resolution and visual acuity (VA) in exudative neovascular AMD (nAMD). Multicentre, retrospective cohort study of treatment naïve nAMD eyes undergoing 3 versus 4 loading doses of aflibercept. Change in VA and fluid resolution on optical coherence tomography (OCT), were evaluated at 8 weeks post loading.

Jun 7, 2023 | nature.com | Shruti Chandra

Author notesThese authors contributed equally: Shruti Chandra, Emanuel Yuquan Tan.

May 31, 2023 | nature.com | Ahmed M. Hagag |Shruti Chandra

AbstractPurposeTo evaluate quantitative morphological changes in macular neovascularisation (MNV) network after aflibercept therapy in neovascular age-related macular degeneration (nAMD) patients. MethodsConsecutive treatment-naïve patients with optical coherence tomography (OCT) angiography confirmed MNV due to nAMD who completed a loading phase of intravitreal aflibercept injections.